These responding men frequently lack MSI detection and while genomic predictors such as tumor mutation burden (TMB) [48], CDK12 loss [23], or LRP1b alterations [49] may identify some men who have extraordinary and durable responses to PD-1 blockade, most men with mCRPC who respond to ICI therapy lack identifiable biomarkers to explain this response. Here, PDCD1 is linked to neoplasm.